Table 2.
Summary of the most frequent molecular alterations in sweat gland neoplasms.
| Diagnosis | Molecular Alteration | Frequency (%) |
|---|---|---|
| Adenoid cystic carcinoma |
MYB::NFIB fusion MYBL1::NFIB fusion |
73–83% 20–23% |
| Cutaneous mixed tumor |
PLAG1 fusion HMGA2 fusion |
33% unknown |
| Cylindroma | CYLD inactivation | near 100% |
| Spiradenoma |
CYLD inactivation ALPK1 p.V1092A mutation |
29% 43% |
| Spiradenocarcinoma |
CYLD inactivation ALPK1 p.V1092A mutation |
8% 33% |
| Hidradenoma |
CRTC1::MAML2 fusion CRTC3::MAML2 fusion |
50–75% rare |
| Hidradenocarcinoma | CRTC1::MAML2 fusion | unknown |
| Myoepithelioma |
EWSR1 fusion FUS fusion |
82% 18% |
| Poroma |
YAP1 fusion NUTM1 fusion |
88% 17–55% |
| Porocarcinoma |
YAP1 fusion NUTM1 fusion |
8–63% 11–54% |
| Secretory carcinoma | ETV6:NTRK3 fusion | near 100% |
| Syringocystadenoma papilliferum and tubular adenoma |
BRAF p.V600E mutation HRAS p.G13R mutation KRAS p.G12D mutation |
50–64% 7–26% rare |